Who is behind this
About PeptideRank
An independent, evidence-first guide to peptide therapy — and to the telehealth market that sells it.
Why this site exists
We went and read 715 advertised prices off 212 sellers' own pages, one at a time, over 86 days between August and October 2026. Here is what that turned up: only 313 of them are a plain monthly rate you can simply pay. The other 402 carry a condition the advertised figure does not state — a “from” price for the smallest dose, a first month that rises, a per-month number you can only get by paying for six. 149 of the 212 would not name a verifiable pharmacy category at all. None of that is knowable from a comparison table someone else compiled, which is why this site does the slow version: read the seller's own page, record the URL and the date, and print what was actually there — including when what was there was nothing.
What we cover
10 ranked boards — sermorelin, tirzepatide, semaglutide, NAD+, Glutathione, PT-141, GHK-Cu, tesamorelin, brand-name GLP-1 and combined weight loss injections — and the telehealth companies that prescribe and price them. Peptide therapy is wider than this and we intend to cover more of it, but a board is only worth publishing once every price on it has been read off the seller's own page and dated — so the roster grows at the speed that work actually takes, and this page lists what exists rather than what is planned.
Who writes it
PeptideRank publishes under 3 editorial-desk bylines covering pricing and provider disclosures, clinical evidence, and women's health. These identify publisher coverage areas, not individual clinicians or a verified staff headcount. PeptideRank is responsible for the research and write-ups. Our method is to distinguish what a trial measured from what remains untested, and to state that uncertainty beside the finding. Funding relationships are listed by provider on conflicts of interest. Full bylines, roles, and contact emails are on the team page.
How the work is done
Every provider price was read off that provider's own public page on a date we record, and “pricing not published” is printed as the finding rather than filled in with an estimate. Where a claim rests on animal or mechanism data, it is labeled separately from anything shown in people. Where a provider has a commercial relationship with us, it is placed first on a ranked list and labeled as such rather than disguised — the assessment printed beside each provider is what a commission cannot buy. The full method, including how we handle being wrong, is on the editorial policy page, and the money is set out in full on how we earn.
What every review checks
The advertised price
Read off the company’s own page, with the link and the date.
What you actually pay
Per month, after prepay terms, dose tiers and first-month jumps.
What is included
Consult, labs, follow-ups, human support, supplies, shipping.
The pharmacy
Whether the company names the pharmacy that fills it, and what kind.
Where it ships
The states the company says it serves.
Refund and cancellation terms, side by side for every company.
How often it is checked
There is no fixed calendar. A review is re-read in full when someone reports an error or its price looks out of date, and each review prints the month it was last checked under its title. The newest checks are from October 2026.
Corrections and contact
A source we missed, a price that has moved, a claim you think is wrong — send it to hello@peptiderank.org or see the contact page. When we were wrong, we fix the page, move its date and list the fix on corrections. Nothing here is medical advice — see the medical disclaimer and talk to a licensed clinician before starting anything.